#United States #San Diego #biopharmaceuticals #Viking Therapeutics #VKTX

Viking Therapeutics to Present at Key Investor Conferences

Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical firm in the clinical stage, is gearing up to showcase its innovative therapies at several upcoming investor conferences. The company's focus is on establishing first-in-class and best-in-class treatments for metabolic and endocrine disorders, making these conferences a significant platform for discussing their developments and future prospects.

Schedule of Investor Conferences

Viking Therapeutics' participation includes:

1. William Blair 45th Annual Growth Stock Conference

• - Dates: June 3-5, 2025
• - Location: Chicago, IL
• - Presentation Details: Viking's management will deliver a corporate presentation and partake in a fireside chat, along with one-on-one meetings with investors.
• - Presentation Timing: June 3, 2025, from 2:00 PM to 2:30 PM Central
• - Fireside Chat Timing: June 3, 2025, from 2:40 PM to 3:10 PM Central

2. Jefferies Global Healthcare Conference

• - Dates: June 3-5, 2025
• - Location: New York, NY
• - Presentation Details: Management will present and engage in one-on-one meetings.
• - Presentation Timing: June 5, 2025, from 11:40 AM to 12:10 PM Central
• - Webcast: Available online via the Viking Therapeutics website following the event.

3. 46th Annual Goldman Sachs Global Healthcare Conference

• - Dates: June 9-11, 2025
• - Location: Miami, FL
• - Participation: Management will engage in one-on-one meetings with investors.

4. Scotiabank Third Annual Healthcare Canadian Investor Day

• - Date: June 17, 2025
• - Location: Toronto, Canada
• - Participation: Viking's team will also be present for one-on-one meetings.

Company Overview and Research Focus

Viking Therapeutics is committed to developing cutting-edge therapies that address metabolic and endocrine diseases. The company's ongoing research and development efforts have led to several compounds currently in clinical trials:

• - VK2735: This is a dual agonist for GLP-1 and GIP receptors aimed at treating metabolic disorders. Initial clinical trials for VK2735 have shown promising results regarding safety and potential clinical benefits. Notably, both Phase 1 and Phase 2 trials indicated a favorable profile.

• - VK2809: This innovative small molecule acts as a selective thyroid hormone receptor beta agonist targeting lipid and metabolic disorders. Recent trials for patients with fatty liver diseases (NAFLD and NASH) have shown significant efficacy, meeting both primary and secondary endpoint outcomes.

• - VK0214: Targeting X-linked adrenoleukodystrophy (X-ALD), this compound has demonstrated safety and efficacy in Phase 1 clinical trials by effectively lowering lipid levels in patients.

With these advancements, the company aims to improve patients' lives through novel therapies backed by rigorous clinical testing and research.

For additional information about Viking Therapeutics, interested parties can visit their website at www.vikingtherapeutics.com.

Conclusion

Viking Therapeutics stands at the forefront of innovation in metabolic and endocrine treatment solutions. Their active participation in significant investor conferences not only showcases their advancements but also emphasizes their commitment to addressing critical health challenges. As they roll out their presentations and engage with investors, the company aims to elevate awareness and excitement around their promising product pipeline.